370 related articles for article (PubMed ID: 2648678)
1. [Interleukin-2 and cancer immunotherapy].
Ogarkov VI; Dobkin AI; Ryzhova EV; Okulov VB; Kiselev OI
Vopr Onkol; 1989; 35(2):141-50. PubMed ID: 2648678
[No Abstract] [Full Text] [Related]
2. In vivo and in vitro activation of NK cytotoxicity with IL-2.
Ibayashi Y; Tokuda Y; Saks ER; Sarna GP; Golub SH
Prog Clin Biol Res; 1987; 244():275-85. PubMed ID: 3498954
[No Abstract] [Full Text] [Related]
3. "Lymphokine activated killing" as treatment for human cancer: clinical extrapolations from laboratory studies with interleukin-2 expanded leukocytes.
Sondel PM; Hank JA; Kohler PC; Chen BP; Sosman J
Prog Clin Biol Res; 1989; 288():151-60. PubMed ID: 2654949
[No Abstract] [Full Text] [Related]
4. The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
Ettinghausen SE; Rosenberg SA
Springer Semin Immunopathol; 1986; 9(1):51-71. PubMed ID: 3523804
[No Abstract] [Full Text] [Related]
5. Adoptive immunotherapy of murine mammary carcinoma using broadly cytotoxic cloned T lymphocytes.
Salup RR; Toth JA; Hiserodt JC; Wolmark N
Prog Clin Biol Res; 1987; 244():39-48. PubMed ID: 2958875
[No Abstract] [Full Text] [Related]
6. [Biotherapy of cancer].
Subirá ML; Brugarolas A
Rev Clin Esp; 1992 Jun; 191(2):102-8. PubMed ID: 1380172
[No Abstract] [Full Text] [Related]
7. Interleukin-2 activated cytotoxic lymphocytes and their application in the intraoperative immunotherapy of local tumors.
Grimm EA
Prog Clin Biol Res; 1987; 244():185-95. PubMed ID: 3498948
[No Abstract] [Full Text] [Related]
8. Human and mouse "LAK" cells expanded in long-term cultures: in vitro and in vivo studies.
Kedar E; Zeira E; Lebendiker Z; Weiss DW; Katan R; Shouval D
Prog Clin Biol Res; 1987; 244():59-75. PubMed ID: 3498959
[No Abstract] [Full Text] [Related]
9. Immunological effects of adoptive immunotherapy with IL-2: an overview.
Kradin R; Yamin R; Kurnick J
Pathol Immunopathol Res; 1988; 7(6):434-41. PubMed ID: 3070529
[No Abstract] [Full Text] [Related]
10. [Immunotherapy of malignant diseases].
Dorval T; Michon J; Tartour E; Fridman WH
Bull Cancer; 1995; 82 Suppl 2():127s-138s. PubMed ID: 7542946
[TBL] [Abstract][Full Text] [Related]
11. The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers.
Talmadge JE; Herberman RB
Cancer Treat Rep; 1986 Jan; 70(1):171-82. PubMed ID: 3510733
[No Abstract] [Full Text] [Related]
12. Radiation therapy and immunotherapy: the value of immunotherapy in the control of local and regional cancer.
Cancer; 1976 Apr; 37(4 Suppl):2108-19. PubMed ID: 769945
[No Abstract] [Full Text] [Related]
13. [Interleukin 2].
Voĭtenok NN
Ter Arkh; 1988; 60(5):42-6. PubMed ID: 3051488
[No Abstract] [Full Text] [Related]
14. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.
Rosenberg SA; Lotze MT
Annu Rev Immunol; 1986; 4():681-709. PubMed ID: 3518753
[No Abstract] [Full Text] [Related]
15. [Thymus hormones in the immunotherapy of malignant neoplasms (a review of the literature)].
Nikol'skiĭ IS
Vrach Delo; 1988 Aug; (8):77-82. PubMed ID: 3061171
[No Abstract] [Full Text] [Related]
16. Natural killer cells and tumor immunity: 1985.
Herberman RB
Year Immunol; 1986; 2():254-60. PubMed ID: 3033946
[No Abstract] [Full Text] [Related]
17. Long-term culture of LAK cells: expansion and activation signals.
Ochoa AC; Migliori RJ; Alter BJ; Sondel PM; Simmons RL; Bach FH
Prog Clin Biol Res; 1987; 244():289-99. PubMed ID: 3116557
[TBL] [Abstract][Full Text] [Related]
18. Tumor-infiltrating lymphocytes: evidence for specific immune reactions against growing cancers in mice and humans.
Topalian SL; Rosenberg SA
Important Adv Oncol; 1990; ():19-41. PubMed ID: 2182519
[No Abstract] [Full Text] [Related]
19. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
Rosenberg SA
Important Adv Oncol; 1986; ():55-91. PubMed ID: 3330541
[No Abstract] [Full Text] [Related]
20. [Cancer immunotherapy: new approaches].
Blay JY; Thomachot MC; Alberti L; Bachelot T; Voorzanger-Rousselot N; Puisieux I; Odin L; Ménétrier-Caux C
Bull Cancer; 2000 Jan; 87(1):97-106. PubMed ID: 10673638
[No Abstract] [Full Text] [Related]
[Next] [New Search]